ABSTRACT
This chapter examines the particular way that circulation is being problematized in global health. It examines struggles over what counts as free and what counts as impeding free circulation that are taking place in the global response to the threat of pandemic influenza and to the event of 2009 H1N1. The chapter explores that the deployment of a notion of health security in global public health has made it harder to imagine and enact modes of global health that actually engage with the social lives of viruses or that tackle health inequities. Since the securitization of HIV, there has been huge investment of money and effort in the global response to HIV and other infectious diseases. Indonesia objected to WHO's role in passing on samples they had provided to the pharmaceutical industry, samples that were commercialized including patent applications filed by US Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH) and via patented vaccine development.
